GLP-1 receptor agonists show promise in treating substance use disorders

A systematic review reveals that GLP-1 receptor agonists may help reduce certain substance use disorders, but findings are inconsistent due to study variability and patient differences.

Third in line: Editas says it may partner up on commercialization of sickle cell gene therapy

Editas Medicine continues to churn along in a solid third place in the race against bluebird bio, and partners Vertex and CRISPR to commercialize the

August 3, 2023

GLP-1 drugs spark disagreements in Trump’s circle

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Hey hey, this is

December 13, 2024

MFGM supplement in infant formula linked to long-term cognitive benefits

Breast milk is widely acknowledged as the most beneficial nutrition for infants, but many families face medical or logistical challenges in breastfeeding. In the U.S.,

August 31, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.